International Journal of Oral Biology

The Korean Academy of Oral Biology (대한구강생물학회)
권호 표지

Establishment of High Throughput Screening System Using Human Umbilical Cord-derived Mesenchymal Stem Cells

  • Park, Eu-Gene (Lab of Dental Regenerative Biotechnology Major, School of Dentistry, Seoul National University) ;
  • Cho, Tae-Jun (Lab of Dental Regenerative Biotechnology Major, School of Dentistry, Seoul National University) ;
  • Oh, Keun-Hee (Department of Biomedical Science, School of Medicine, Seoul National University) ;
  • Kwon, Soon-Keun (Lab of Dental Regenerative Biotechnology Major, School of Dentistry, Seoul National University) ;
  • Lee, Dong-Sup (Department of Biomedical Science, School of Medicine, Seoul National University) ;
  • Park, Seung-Bum (Department of Chemistry, Seoul National University) ;
  • Cho, Jae-Jin (Lab of Dental Regenerative Biotechnology Major, School of Dentistry, Seoul National University)
  • Received : 2012.02.28
  • Accepted : 2012.06.19
  • Published : 2012.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The use of high throughput screening (HTS) in drug development is principally for the selection new drug candidates or screening of chemical toxicants. This system minimizes the experimental environment and allows for the screening of candidates at the same time. Umbilical cord-derived stem cells have some of the characteristics of fetal stem cell and have several advantages such as the ease with which they can be obtained and lack of ethical issues. To establish a HTS system, optimized conditions that mimic typical cell culture conditions in a minimal space such as 96 well plates are needed for stem cell growth. We have thus established a novel HTS system using human umbilical cord derived-mesenchymal stem cells (hUC-MSCs). To determine the optimal cell number, hUC-MSCs were serially diluted and seeded at 750, 500, 200 and 100 cells per well on 96 well plates. The maintenance efficiencies of these dilutions were compared for 3, 7, 9, and 14 days. The fetal bovine serum (FBS) concentration (20, 10, 5 and 1%) and the cell numbers (750, 500 and 200 cells/well) were compared for 3, 5 and 7 days. In addition, we evaluated the optimal conditions for cell cycle block. These four independent optimization experiments were conducted using an MTT assay. In the results, the optimal conditions for a HTS system using hUC-MSCs were determined to be 300 cell/well cultured for 8 days with 1 or 5% FBS. In addition, we demonstrated that the optimal conditions for a cell cycle block in this culture system are 48 hours in the absence of FBS. In addition, we selected four types of novel small molecule candidates using our HTS system which demonstrates the feasibility if using hUC-MSCs for this type of screen. Moreover, the four candidate compounds can be tested for stem cell research application.

Keywords

References

  1. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991; 9:641-650.
  2. Xu Y, Malladi P, Wagner DR, Longaker MT. Adiposederived mesenchymal cells as a potential cell source for skeletal regeneration. Curr Opin Mol Ther. 2005;7:300-305.
  3. Bieback K, Kluter H. Mesenchymal stromal cells from umbilical cord blood. Curr Stem Cell Res Ther. 2007;2:310-323.
  4. Tsai MS, Lee JL, Chang YJ, Hwang SM. Isolation of human multipotent mesenchymal stem cells from secondtrimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod. 2004;19:1450-1456.
  5. Igura K, Zhang X, Takahashi K, Mitsuru A, Yamaguchi S, et al. Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. Cytotherapy. 2004;6:543-553.
  6. Shi S, Gronthos S. Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. J Bone Miner Res. 2003;18:696-704.
  7. Rotter N, Oder J, Schlenke P, Lindner U, Bohrnsen F, et al. Isolation and characterization of adult stem cells from human salivary glands. Stem Cells Dev. 2008;17:509-518.
  8. De Bari C, Dell'Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. 2001;44:1928-1942.
  9. Hanson SE, Kim J, Johnson BH, Bradley B, Breunig MJ, et al. Characterization of mesenchymal stem cells from human vocal fold fibroblasts. Laryngoscope. 2010;120:546-551.
  10. Girdlestone J, Limbani VA, Cutler AJ, Navarrete CV. Efficient expansion of mesenchymal stromal cells from umbilical cord under low serum conditions. Cytotherapy. 2009;11:738-748.
  11. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317.
  12. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3:393-403.
  13. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol. 2007;213:341-347.
  14. Satija NK, Singh VK, Verma YK, Gupta P, Sharma S, et al. Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. J Cell Mol Med. 2009;13:4385-4402.
  15. Sobolewski K, Bankowski E, Chyczewski L, Jaworski S. Collagen and glycosaminoglycans of Wharton's jelly. Biol Neonate. 1997;71:11-21.
  16. Covas DT, Siufi JL, Silva AR, Orellana MD. Isolation and culture of umbilical vein mesenchymal stem cells. Braz J Med Biol Res. 2003;36:1179-1183.
  17. Weiss ML, Troyer DL. Stem cells in the umbilical cord. Stem Cell Rev. 2006;2:155-162.
  18. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 2000;28:875-884.
  19. Rao MS, Mattson MP. Stem cells and aging: expanding the possibilities. Mech Ageing Dev. 2001;122:713-734.
  20. Huang AH, Motlekar NA, Stein A, Diamond SL, Shore EM, et al. High-throughput screening for modulators of mesenchymal stem cell chondrogenesis. Ann Biomed Eng. 2008;36:1909-1921.
  21. Cotticelli MG, Rasmussen L, Kushner NL, McKellip S, Sosa MI, et al. Primary and Secondary Drug Screening Assays for Friedreich Ataxia. J Biomol Screen. 2011
  22. Varma H, Lo DC, Stockwell BR. High-Throughput and High-Content Screening for Huntington's Disease Therapeutics. In: Lo DC, Hughes RE, editors. Neurobiology of Huntington's Disease: Applications to Drug Discovery. Boca Raton (FL). 2011
  23. Alves H, Dechering K, Van Blitterswijk C, De Boer J. High-throughput assay for the identification of compounds regulating osteogenic differentiation of human mesenchymal stromal cells. PLoS One. 2011;6:e26678.
  24. Penick KJ, Solchaga LA, Welter JF. High-throughput aggregate culture system to assess the chondrogenic potential of mesenchymal stem cells. Biotechniques. 2005;39:687-691.
  25. Welter JF, Solchaga LA, Penick KJ. Simplification of aggregate culture of human mesenchymal stem cells as a chondrogenic screening assay. Biotechniques. 2007;42:732, 734-737.
  26. Desbordes SC, Placantonakis DG, Ciro A, Socci ND, Lee G, et al. High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells. Cell Stem Cell. 2008;2:602-612.
  27. Brey DM, Motlekar NA, Diamond SL, Mauck RL, Garino JP, et al. High-throughput screening of a small molecule library for promoters and inhibitors of mesenchymal stem cell osteogenic differentiation. Biotechnol Bioeng. 2011;108:163-174.
  28. Ding S, Wu TY, Brinker A, Peters EC, Hur W, et al. Synthetic small molecules that control stem cell fate. Proc Natl Acad Sci U S A. 2003;100:7632-7637.
  29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
  30. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 1991;2:209-214.